User profiles for A. Plé
Le Anh Ngoc, PhDSwinburne University of Technology Vietnam Verified email at swin.edu.au Cited by 1014 |
Inflammatory bowel disease therapeutic strategies by modulation of the microbiota: how and when to introduce pre-, pro-, syn-, or postbiotics?
A Lê, M Mantel, J Marchix, M Bodinier… - American Journal …, 2022 - journals.physiology.org
… Indeed, apple pectin increased in vitro the abundance of butyrate-producing bacteria,
including F. prausnitzii, and butyrate concentrations in feces from patients with UC and CD (49). …
including F. prausnitzii, and butyrate concentrations in feces from patients with UC and CD (49). …
[HTML][HTML] Docosahexaenoic acid reduces suppressive and migratory functions of CD4CD25 regulatory T-cells
A Yessoufou, A Plé, K Moutairou, A Hichami… - Journal of Lipid …, 2009 - ASBMB
Immunological tolerance is one of the fundamental aspects of the immune system. The CD4
+ CD25 + regulatory T (Treg) cells have emerged as key players in the development of …
+ CD25 + regulatory T (Treg) cells have emerged as key players in the development of …
Docosahexaenoic acid induces increases in [Ca2+] i via inositol 1, 4, 5-triphosphate production and activates protein kinase Cγ and-δ via phosphatidylserine binding …
We investigated, in monocytic leukemia U937 cells, the effects of docosahexaenoic acid (DHA;
22:6 n-3) on calcium signaling and determined the implication of phospholipase C (PLC) …
22:6 n-3) on calcium signaling and determined the implication of phospholipase C (PLC) …
N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally …
…, RA Norman, A Olivier, L Otterbein, PA Plé… - Journal of medicinal …, 2006 - ACS Publications
… Plé … Plé - Centre de Recherches, AstraZeneca, ZISE La Pompelle, BP 1050, 51689 Reims
Cedex 2, France, and AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, …
Cedex 2, France, and AstraZeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, …
Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase …
…, AP Thomas, C Johnstone, PA Plé… - Journal of medicinal …, 2002 - ACS Publications
We have previously shown that 4-anilinoquinazolines can be potent inhibitors of vascular
endothelial growth factor (VEGF) receptor (Flt-1 and KDR) tyrosine kinase activity. A novel …
endothelial growth factor (VEGF) receptor (Flt-1 and KDR) tyrosine kinase activity. A novel …
Design and structure− activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors
…, C Johnstone, ESE Stokes, PA Plé… - Journal of medicinal …, 1999 - ACS Publications
A series of substituted 4-anilinoquinazolines and related compounds were synthesized as
potential inhibitors of vascular endothelial growth factor (VEGF) receptor (Flt and KDR) …
potential inhibitors of vascular endothelial growth factor (VEGF) receptor (Flt and KDR) …
[HTML][HTML] Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530
…, RW Wilkinson, P Elvin, B Boyer, N Carragher, PA Plé… - Molecular …, 2009 - Elsevier
AZD0530, an orally available Src inhibitor, demonstrated potent antimigratory and anti-invasive
effects in vitro, and inhibited metastasis in a murine model of bladder cancer. …
effects in vitro, and inhibited metastasis in a murine model of bladder cancer. …
Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src
PA Ple, TP Green, LF Hennequin… - Journal of medicinal …, 2004 - ACS Publications
Deregulated activity of the nonreceptor tyrosine kinase c-Src is believed to result in signal
transduction, cytoskeletal and adhesion changes, ultimately promoting a tumor-invasive …
transduction, cytoskeletal and adhesion changes, ultimately promoting a tumor-invasive …
Development and validation of a simultaneous quantification method of ruxolitinib, vismodegib, olaparib, and pazopanib in human plasma using liquid …
C Pressiat, HH Huynh, A Ple… - Therapeutic Drug …, 2018 - journals.lww.com
Background: A simple, rapid, and sensitive liquid chromatography coupled with tandem mass
spectrometry method has been developed and validated for the quantification of ruxolitinib…
spectrometry method has been developed and validated for the quantification of ruxolitinib…
Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases
PA Plé, F Jung, S Ashton, L Hennequin, R Laine… - Bioorganic & medicinal …, 2012 - Elsevier
… Plé a , Frédéric Jung a , Sue Ashton b , Laurent Hennequin a , Romuald Laine b , Rémy
Morgentin a , Georges Pasquet a , Sian Taylor b … Plé, P.; Jung, FH Patent WO …
Morgentin a , Georges Pasquet a , Sian Taylor b … Plé, P.; Jung, FH Patent WO …